Caregen Co.Ltd (214370) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.019x

Based on the latest financial reports, Caregen Co.Ltd (214370) has a cash flow conversion efficiency ratio of 0.019x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.16 Billion ≈ $2.82 Million USD) by net assets (₩216.88 Billion ≈ $146.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Caregen Co.Ltd market capitalisation for the company's overall valuation and market capitalisation.

Caregen Co.Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how Caregen Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Caregen Co.Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Caregen Co.Ltd ranked by their cash flow conversion efficiency. Explore Caregen Co.Ltd cash flow quality index to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Transcom Inc
TW:5222
0.028x
Phihong Technology Co Ltd
TW:2457
-0.063x
Avalue Technology
TWO:3479
0.001x
Pan Malaysia Holdings Bhd
KLSE:1287
-0.947x
Prudential plc
LSE:PRU
0.073x
Rubellite Energy Inc
TO:RBY
0.090x
Guangzhou Improve Med Instrument
SHE:300030
0.104x
Huafang Co Ltd
SHG:600448
0.148x

Annual Cash Flow Conversion Efficiency for Caregen Co.Ltd (2015–2024)

The table below shows the annual cash flow conversion efficiency of Caregen Co.Ltd from 2015 to 2024. View Caregen Co.Ltd (214370) share price today for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩222.98 Billion
≈ $151.11 Million
₩13.49 Billion
≈ $9.14 Million
0.060x -51.93%
2023-12-31 ₩227.30 Billion
≈ $154.04 Million
₩28.60 Billion
≈ $19.38 Million
0.126x +198.20%
2022-12-31 ₩215.98 Billion
≈ $146.37 Million
₩-27.68 Billion
≈ $-18.76 Million
-0.128x -151.82%
2021-12-31 ₩209.72 Billion
≈ $142.12 Million
₩51.86 Billion
≈ $35.14 Million
0.247x +64.84%
2020-12-31 ₩205.16 Billion
≈ $139.03 Million
₩30.78 Billion
≈ $20.86 Million
0.150x -53.27%
2019-12-31 ₩217.01 Billion
≈ $147.06 Million
₩69.66 Billion
≈ $47.21 Million
0.321x +1063.53%
2018-12-31 ₩204.75 Billion
≈ $138.76 Million
₩-6.82 Billion
≈ $-4.62 Million
-0.033x -116.13%
2017-12-31 ₩231.83 Billion
≈ $157.11 Million
₩47.88 Billion
≈ $32.45 Million
0.207x +403.39%
2016-12-31 ₩234.11 Billion
≈ $158.65 Million
₩-15.94 Billion
≈ $-10.80 Million
-0.068x -1180.76%
2015-12-31 ₩248.87 Billion
≈ $168.66 Million
₩1.57 Billion
≈ $1.06 Million
0.006x --

About Caregen Co.Ltd

KQ:214370 Korea Pharmaceuticals
Market Cap
$297.04 Million
₩438.31 Billion KRW
Market Cap Rank
#14978 Global
#485 in Korea
Share Price
₩40800.00
Change (1 day)
-0.97%
52-Week Range
₩40800.00 - ₩150100.00
All Time High
₩150100.00
About

Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands. It also provides medical devices under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG S… Read more